Profile data is unavailable for this security.
About the company
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.
- Revenue in USD (TTM)1.00m
- Net income in USD-20.18m
- Incorporated2015
- Employees16.00
- LocationvTv Therapeutics Inc3980 Premier Dr, Suite 310HIGH POINT 27265United StatesUSA
- Phone+1 (336) 841-0300
- Fax+1 (336) 841-0310
- Websitehttps://vtvtherapeutics.com/